Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Nuclear Medicine

Free Subscription Articles published in Neurology Retrieve available abstracts of 86 articles: HTML format

Single Articles

February 2026
1. RANI N, Moghekar A, Callow DD, Alm KH, et al
   Association Between Longitudinal Rate of Change in CSF Biomarkers and Subsequent Tau PET Burden in Early Braak Stages.
   Neurology. 2026;106:e214620.
   PubMed     Abstract available
   
   
   
2. SUN Y, Na HK, Jeon S, Ye BS, et al
   Cerebral Perfusion and Motor Deficits in Drug-Induced Parkinsonism: A Dual-Phase (18)F-FP-CIT PET Study.
   Neurology. 2026;106:e214573.
   PubMed     Abstract available
   
   
   January 2026
3. AZAD N, Avery RJ, Crews M, Schuele SU, et al
   Use of Ictal-Interictal SPECT in Localization of Surface-EEG-Negative Insular Epilepsy.
   Neurology. 2026;106:e214529.
   PubMed    
   
   
   
4. LI CH, Fan SP, Chen PS, Chang YY, et al
   Plasma pTau217 and Neurofilament Light Chain as Differentiative Markers for Progressive Supranuclear Palsy From Parkinson Disease.
   Neurology. 2026;106:e214406.
   PubMed     Abstract available
   
   
   
5. FERREIRA PCL, Bellaver B, Povala G, Bauer-Negrini G, et al
   Evaluating Plasma p-tau217 as an Endpoint for Alzheimer Disease Clinical Trials.
   Neurology. 2026;106:e214441.
   PubMed     Abstract available
   
   
   
6. JUNG YH, Cho J, Lee SY, Seo HE, et al
   Impact of Cerebral Microbleeds on Tau-Associated Cognitive and Structural Decline.
   Neurology. 2026;106:e214453.
   PubMed     Abstract available
   
   
   December 2025
7. LIN M, Zeng Q, Zhong S, Nie S, et al
   Association Between Choroid Plexus Morphological Alterations, Alzheimer Pathologies, and Cognitive Impairment: A Longitudinal Study.
   Neurology. 2025;105:e213953.
   PubMed     Abstract available
   
   
   
8. KRELL-ROESCH J, Syrjanen JA, Hansen AL, Vemuri P, et al
   Physical and Cognitive Activities and Trajectories of AD Neuroimaging Biomarkers: Longitudinal Analysis in the Mayo Clinic Study of Aging.
   Neurology. 2025;105:e214405.
   PubMed     Abstract available
   
   
   November 2025
9. RAMOS-CEJUDO J, Beiser AS, Lu S, Tanner JA, et al
   Association of Platelet Aggregation With Markers of Alzheimer Disease Pathology in Middle-Aged Participants of the Framingham Heart Study.
   Neurology. 2025;105:e214314.
   PubMed     Abstract available
   
   
   
10. ORSO B, Mattioli P, Fama F, Massa F, et al
    Uncovering Clinical and Functional Neuroimaging Characteristics of Overt Stage Phenotypes Within the alpha-Synucleinopathy Spectrum.
    Neurology. 2025;105:e214253.
    PubMed     Abstract available
    
    
    
11. LOPEZ-MARTOS D, Suarez-Calvet M, Mila-Aloma M, Gispert JD, et al
    Longitudinal Associations of Multimodal Core 1 Alzheimer Disease Biomarkers With Cognition in Aging and Preclinical Alzheimer Disease.
    Neurology. 2025;105:e214308.
    PubMed     Abstract available
    
    
    October 2025
12. TRUDEL L, Therriault J, Macedo AC, Servaes S, et al
    Implication for Clinical Trials From Longitudinal Tau-PET Accumulation Across Biological Alzheimer Disease Stages.
    Neurology. 2025;105:e214111.
    PubMed     Abstract available
    
    
    
13. CARVALHO DZ, Kolla BP, McCarter SJ, St Louis EK, et al
    Associations of Chronic Insomnia, Longitudinal Cognitive Outcomes, Amyloid-PET, and White Matter Changes in Cognitively Normal Older Adults.
    Neurology. 2025;105:e214155.
    PubMed     Abstract available
    
    
    
14. COLLIJ LE, Coomans EM
    Are Tau-PET Subtypes Ready for Clinical Use? Putting Visual Reads to the Test.
    Neurology. 2025;105:e214188.
    PubMed    
    
    
    
15. BOCCALINI C, Mathoux G, Hristovska I, Ribaldi F, et al
    Visual Classification of Tau-PET Detects 4 Subtypes With Different Long-Term Outcomes.
    Neurology. 2025;105:e213950.
    PubMed     Abstract available
    
    
    September 2025
16. CHAHINE L, Rosso AL, Troidl I, Ganguli M, et al
    Features of Prodromal Parkinson Disease and Dopaminergic Neurotransmission in Community-Dwelling Older Adults.
    Neurology. 2025;105:e214037.
    PubMed     Abstract available
    
    
    
17. YIM S, Park S, Lim K, Kang H, et al
    Integrating MRI Volume and Plasma p-Tau217 for Amyloid Risk Stratification in Early-Stage Alzheimer Disease.
    Neurology. 2025;105:e213954.
    PubMed     Abstract available
    
    
    
18. WANG X, Ye T, Zhou W, Zhang J, et al
    Association of Distinct Initial beta-Amyloid Levels With Tau Pathology Expansion Beyond the Entorhinal Cortex.
    Neurology. 2025;105:e214041.
    PubMed     Abstract available
    
    
    
19. KAPASI A, James BD, Yu L, Sood A, et al
    Mixed Pathologies and Cognitive Outcomes in Persons Considered for Anti-Amyloid Treatment Eligibility Assessment: A Community-Based Study.
    Neurology. 2025;105:e214004.
    PubMed     Abstract available
    
    
    
20. BROWN TM, James SN, Nicholas JM, Keuss S, et al
    Association of Increase in White Matter Hyperintensity Volume With Rate of Hippocampal Atrophy in a Population-Based Study of Aging.
    Neurology. 2025;105:e213975.
    PubMed     Abstract available
    
    
    August 2025
21. HU W, Nguyen TN, Qureshi M, Chen Z, et al
    Noncontrast CT vs CT Perfusion Imaging in Patients With Basilar Artery Occlusion: Analysis of the ATTENTION and ATTENTION IA Trials.
    Neurology. 2025;105:e213911.
    PubMed     Abstract available
    
    
    July 2025
22. WANG S, Zhang F, Zeng Q, Hong H, et al
    Association of Superficial White Matter Microstructure With Cortical Pathology Deposition Across Early Stages of the AD Continuum.
    Neurology. 2025;105:e213666.
    PubMed     Abstract available
    
    
    
23. BARNARD L, Botha H, Corriveau-Lecavalier N, Graff-Radford J, et al
    An FDG-PET-Based Machine Learning Framework to Support Neurologic Decision-Making in Alzheimer Disease and Related Disorders.
    Neurology. 2025;105:e213831.
    PubMed     Abstract available
    
    
    
24. VANDERLIP CR, Stark CEL
    Time Course and Severity of Cognitive Changes as a Function of Abeta Positivity and APOE Genotype in Alzheimer Disease.
    Neurology. 2025;105:e213853.
    PubMed     Abstract available
    
    
    June 2025
25. DUBBELMAN MA, Liu A, Donohue MC, Langford O, et al
    Changes in Daily Functioning in Association With Tau and Amyloid Among Unimpaired Older Adults With and Without Elevated Amyloid.
    Neurology. 2025;104:e213775.
    PubMed     Abstract available
    
    
    
26. GONZALEZ-ORTIZ F, Kirsebom BE, Yakoub Y, Gundersen JK, et al
    Associations Between Changes in Levels of Phosphorylated Tau and Severity of Cognitive Impairment in Early Alzheimer Disease.
    Neurology. 2025;104:e213676.
    PubMed     Abstract available
    
    
    
27. MENDES AJ, Ribaldi F, Pievani M, Boccalini C, et al
    Validating the Amyloid Cascade Through the Revised Criteria of Alzheimer's Association Workgroup 2024 for Alzheimer Disease.
    Neurology. 2025;104:e213675.
    PubMed     Abstract available
    
    
    May 2025
28. MUJANOVIC A, Yogendrakumar V, Ng FC, Gattringer T, et al
    Effect of Thrombolytics on Delayed Reperfusion After Incomplete Thrombectomy: Target Trial Emulation.
    Neurology. 2025;104:e213641.
    PubMed     Abstract available
    
    
    
29. OURRY V, Fajardo-Valdez A, Soucy JP, Poirier J, et al
    Amyloid and Tau Pathology in Cognitively Unimpaired Individuals With a Parental History of Alzheimer Disease: Role of Sex and Parent's Sex.
    Neurology. 2025;104:e213507.
    PubMed     Abstract available
    
    
    April 2025
30. BONOMI CG, Martorana A, Motta C, Serafini C, et al
    Autonomic Dysfunction in Patients With Dementia With Lewy Bodies and Its Relationship With Nigrostriatal Denervation.
    Neurology. 2025;104:e213463.
    PubMed     Abstract available
    
    
    
31. DEMEESTERE J, Verhaaren BFJ, Christensen S, Wouters A, et al
    Underestimation of Follow-Up Infarct Volume by Acute CT Perfusion Imaging.
    Neurology. 2025;104:e213439.
    PubMed     Abstract available
    
    
    March 2025
32. TURPIN AL, Felisatti F, Chauveau L, Haudry S, et al
    Association Between Lifestyle at Different Life Periods and Brain Integrity in Older Adults.
    Neurology. 2025;104:e213347.
    PubMed     Abstract available
    
    
    
33. LI XY, Tang G, Lu J, Zhao Y, et al
    Self-Reported REM Sleep Behavior Disorder in Patients With Progressive Supranuclear Palsy: Clinical and (18)F-Florzolotau PET Imaging Findings.
    Neurology. 2025;104:e213376.
    PubMed     Abstract available
    
    
    
34. PALERMO G, Francesconi A, Bellini G, Morganti R, et al
    Involvement of the Nigrostriatal Pathway in Patients With Idiopathic Normal Pressure Hydrocephalus and Parkinsonism.
    Neurology. 2025;104:e213352.
    PubMed     Abstract available
    
    
    February 2025
35. LIANG J, Hussainy S, Lee SM, Wu G, et al
    Association of Polygenic Risk Score for 5 Diseases With Alzheimer Disease Progression, Biomarkers, and Amyloid Deposition.
    Neurology. 2025;104:e210250.
    PubMed     Abstract available
    
    
    
36. BORNHORST JA, Lundgreen CS, Weigand SD, Figdore DJ, et al
    Quantitative Assessment of the Effect of Chronic Kidney Disease on Plasma P-Tau217 Concentrations.
    Neurology. 2025;104:e210287.
    PubMed     Abstract available
    
    
    
37. JOUTSA J, Rinne JO, Niemi KJ, Karrasch M, et al
    Progression of Amyloid Accumulation in Late Adulthood Among People With Childhood-Onset Epilepsy.
    Neurology. 2025;104:e210303.
    PubMed     Abstract available
    
    
    
38. GARCIA-ESPERON C, Berry-Noronha A, Di Bartolo A, Green DS, et al
    Arterial Input Function Dispersal on Acute Brain CT Perfusion Scan in Patients With Acute Stroke and an Intracardiac Thrombus.
    Neurology. 2025;104:e210256.
    PubMed     Abstract available
    
    
    January 2025
39. QUISPIALAYA KM, Therriault J, Aliaga A, Benedet AL, et al
    Comparison of Plasma p-tau217 and [(18)F]FDG-PET for Identifying Alzheimer Disease in People With Early-Onset or Atypical Dementia.
    Neurology. 2025;104:e210211.
    PubMed     Abstract available
    
    
    
40. RODRIGUEZ-BAZ I, Benejam B, Morcillo-Nieto AO, Vaque-Alcazar L, et al
    Posterior Cortical Atrophy Due to Alzheimer Disease in a Person With Down Syndrome: A Case Report.
    Neurology. 2025;104:e210179.
    PubMed     Abstract available
    
    
    
41. CHEN Z, Jiang D, Kong Y, Zhang J, et al
    Association of Glymphatic Function With Clinical Characteristics in Patients With Clinical and Asymptomatic Creutzfeldt-Jakob Disease.
    Neurology. 2025;104:e210055.
    PubMed     Abstract available
    
    
    December 2024
42. YOO HS, Lee YG, Sohn YH, Yun M, et al
    Association of Relative Brain Hyperperfusion Independent of Dopamine Depletion With Motor Dysfunction in Patients With Parkinson Disease.
    Neurology. 2024;103:e210077.
    PubMed     Abstract available
    
    
    
43. YOO HS, Kim HK, Na HK, Kang S, et al
    Association of Striatal Dopamine Depletion and Brain Metabolism Changes With Motor and Cognitive Deficits in Patients With Parkinson Disease.
    Neurology. 2024;103:e210105.
    PubMed     Abstract available
    
    
    
44. BOCCALINI C, Dodich A, Scheffler M, Lagana V, et al
    In Vivo Tau and Neurodegeneration Imaging in a Family With the Presenilin 1 Met146Leu Pathogenic Variant.
    Neurology. 2024;103:e210103.
    PubMed     Abstract available
    
    
    
45. BISCHOF GN, Jaeger E, Giehl K, Jessen F, et al
    Cortical Tau Aggregation Patterns Associated With Apraxia in Patients With Alzheimer Disease.
    Neurology. 2024;103:e210062.
    PubMed     Abstract available
    
    
    
46. VELLIEUX G, Apartis E, Baudin P, Del Rio Quinones MA, et al
    Multimodal Assessment of the Origin of Myoclonus in Lance-Adams Syndrome.
    Neurology. 2024;103:e209994.
    PubMed     Abstract available
    
    
    November 2024
47. PENSATO U, Bosshart S, Stebner A, Rohr A, et al
    Effect of Hemoglobin and Blood Glucose Levels on CT Perfusion Ischemic Core Estimation: A Post Hoc Analysis of the ESCAPE-NA1 Trial.
    Neurology. 2024;103:e209939.
    PubMed     Abstract available
    
    
    
48. MICHAELSON NM, Klawiter EC, Singhal T
    Journal Club: PET Imaging in Multiple Sclerosis and Its Prognostic Implications.
    Neurology. 2024;103:e210047.
    PubMed    
    
    
    
49. LAM AD, Thibault EG, Mayblyum DV, Hsieh S, et al
    Association of Seizure Foci and Location of Tau and Amyloid Deposition and Brain Atrophy in Patients With Alzheimer Disease and Seizures.
    Neurology. 2024;103:e209920.
    PubMed     Abstract available
    
    
    
50. HAZAN J, Liu KY, Costello H, Isaacs JD, et al
    Challenges in a Biological Definition of Alzheimer Disease.
    Neurology. 2024;103:e209884.
    PubMed     Abstract available
    
    
    
51. WATANABE H, Duffy JR, Clark H, Machulda MM, et al
    Primary Progressive Aphasia Lacking Core Features of Nonfluent and Semantic Variants: Clinical, Neuroimaging, and Neuropathologic Features.
    Neurology. 2024;103:e209924.
    PubMed     Abstract available
    
    
    August 2024
52. ROMOLI M, Marinoni G, Tagliabue L, Capozza A, et al
    (18F)Flutemetamol-PET Aided Classification of Cerebral Amyloid Angiopathy: A Multicenter Study.
    Neurology. 2024;103:e209719.
    PubMed     Abstract available
    
    
    
53. VAN DER VEERE PJ, Hoogland J, Visser LNC, Van Harten AC, et al
    Predicting Cognitive Decline in Amyloid-Positive Patients With Mild Cognitive Impairment or Mild Dementia.
    Neurology. 2024;103:e209605.
    PubMed     Abstract available
    
    
    
54. NISHIDA A, Shima A, Kambe D, Furukawa K, et al
    Frontoparietal-Striatal Network and Nucleus Basalis Modulation in Patients With Parkinson Disease and Gait Disturbance.
    Neurology. 2024;103:e209606.
    PubMed     Abstract available
    
    
    
55. WANG J, Ackley S, Woodworth DC, Sajjadi SA, et al
    Associations of Amyloid Burden, White Matter Hyperintensities, and Hippocampal Volume With Cognitive Trajectories in the 90+ Study.
    Neurology. 2024;103:e209665.
    PubMed     Abstract available
    
    
    July 2024
56. MUJANOVIC A, Ng FC, Branca M, Deutschmann HA, et al
    External Validation of a Model for Persistent Perfusion Deficit in Patients With Incomplete Reperfusion After Thrombectomy: EXTEND-PROCEED.
    Neurology. 2024;103:e209401.
    PubMed     Abstract available
    
    
    
57. OH Y, Kim JS, Lyoo CH, Park G, et al
    Spatiotemporal Progression Patterns of Dopamine Availability and Deep Gray Matter Volume in Parkinson Disease-Related Cognitive Impairment.
    Neurology. 2024;103:e209498.
    PubMed     Abstract available
    
    
    
58. XIA Y, Dore V, Fripp J, Bourgeat P, et al
    Association of Basal Forebrain Atrophy With Cognitive Decline in Early Alzheimer Disease.
    Neurology. 2024;103:e209626.
    PubMed     Abstract available
    
    
    
59. MASTENBROEK SE, Sala A, Vallez Garcia D, Shekari M, et al
    Continuous beta-Amyloid CSF/PET Imbalance Model to Capture Alzheimer Disease Heterogeneity.
    Neurology. 2024;103:e209419.
    PubMed     Abstract available
    
    
    June 2024
60. BABULAL GM, Chen L, Murphy SA, Carr DB, et al
    Predicting Driving Cessation Among Cognitively Normal Older Drivers: The Role of Alzheimer Disease Biomarkers and Clinical Assessments.
    Neurology. 2024;102:e209426.
    PubMed     Abstract available
    
    
    
61. YE R, Goodheart AE, Locascio JJ, Peterec E, et al
    Differential Vulnerability of Hippocampal Subfields to Amyloid and Tau Deposition in the Lewy Body Diseases.
    Neurology. 2024;102:e209460.
    PubMed     Abstract available
    
    
    
62. JADICK MF, Robinson T, Farrell ME, Klinger H, et al
    Associations Between Self and Study Partner Report of Cognitive Decline With Regional Tau in a Multicohort Study.
    Neurology. 2024;102:e209447.
    PubMed     Abstract available
    
    
    
63. DI LUCA DG, Perlmutter JS
    Time for Clinical Dopamine Transporter Scans in Parkinsonism?: Not DAT Yet.
    Neurology. 2024;102:e209558.
    PubMed    
    
    
    
64. HASTINGS A, Cullinane P, Wrigley S, Revesz T, et al
    Neuropathologic Validation and Diagnostic Accuracy of Presynaptic Dopaminergic Imaging in the Diagnosis of Parkinsonism.
    Neurology. 2024;102:e209453.
    PubMed     Abstract available
    
    
    May 2024
65. RUS T, Cuderman A, Georgiev D
    Parkinsonism Associated With Traumatic Hemorrhage in Substantia Nigra: Role of Presynaptic Dopaminergic Imaging.
    Neurology. 2024;102:e209384.
    PubMed    
    
    
    
66. COURTNEY MR, Antonic-Baker A, Chen Z, Sinclair B, et al
    Association of Localizing (18)F-FDG-PET Hypometabolism and Outcome Following Epilepsy Surgery: Systematic Review and Meta-Analysis.
    Neurology. 2024;102:e209304.
    PubMed     Abstract available
    
    
    
67. BARATEAU L, Krache A, Da Costa A, Lecendreux M, et al
    Microglia Density and Its Association With Disease Duration, Severity, and Orexin Levels in Patients With Narcolepsy Type 1.
    Neurology. 2024;102:e209326.
    PubMed     Abstract available
    
    
    April 2024
68. WEINSTEIN G, Kojis DJ, Ghosh S, Beiser AS, et al
    Association of Neurotrophic Factors at Midlife With In Vivo Measures of beta-Amyloid and Tau Burden 15 Years Later in Dementia-Free Adults.
    Neurology. 2024;102:e209198.
    PubMed     Abstract available
    
    
    
69. CAI Y, Shi D, Lan G, Chen L, et al
    Association of beta-Amyloid, Microglial Activation, Cortical Thickness, and Metabolism in Older Adults Without Dementia.
    Neurology. 2024;102:e209205.
    PubMed     Abstract available
    
    
    
70. GREENBERG S, Battioui C, Lu M, Biffi A, et al
    ARIA Insights from the Donanemab Trials (P1-9.001).
    Neurology. 2024;102.
    PubMed     Abstract available
    
    
    
71. APPLETON J, Funk Q, Fregonara PZ, Yu M, et al
    Neuroinflammation Co-localizes Highly with Tau in Mild Cognitive Impairment from Early Onset Alzheimer's Disease (N4.002).
    Neurology. 2024;102.
    PubMed     Abstract available
    
    
    March 2024
72. HONIG M, Altomare D, Caprioglio C, Collij L, et al
    Association Between Years of Education and Amyloid Burden in Patients With Subjective Cognitive Decline, MCI, and Alzheimer Disease.
    Neurology. 2024;102:e208053.
    PubMed     Abstract available
    
    
    
73. ACKLEY S, Calmasini C, Bouteloup V, Hill-Jarrett TG, et al
    Contribution of Global Amyloid-PET Imaging for Predicting Future Cognition in the MEMENTO Cohort.
    Neurology. 2024;102:e208054.
    PubMed     Abstract available
    
    
    February 2024
74. RAHAYEL S, Postuma R, Baril AA, Misic B, et al
    (99m)Tc-HMPAO SPECT Perfusion Signatures Associated With Clinical Progression in Patients With Isolated REM Sleep Behavior Disorder.
    Neurology. 2024;102:e208015.
    PubMed     Abstract available
    
    
    January 2024
75. PALLEIS C, Franzmeier N, Weidinger E, Bernhardt AM, et al
    Association of Neurofilament Light Chain, [(18)F]PI-2620 Tau-PET, TSPO-PET, and Clinical Progression in Patients With beta-Amyloid-Negative CBS.
    Neurology. 2024;102:e207901.
    PubMed     Abstract available
    
    
    December 2023
76. HANSEEUW BJ, Jacobs HIL, Schultz AP, Buckley RF, et al
    Association of Pathologic and Volumetric Biomarker Changes With Cognitive Decline in Clinically Normal Adults.
    Neurology. 2023;101:e2533-e2544.
    PubMed     Abstract available
    
    
    November 2023
77. YOON SH, Kim HK, Lee JH, Chun JH, et al
    Association of Sleep Disturbances With Brain Amyloid and Tau Burden, Cortical Atrophy, and Cognitive Dysfunction Across the AD Continuum.
    Neurology. 2023;101:e2162-e2171.
    PubMed     Abstract available
    
    
    October 2023
78. THEIS H, Bischof GN, Bruggemann N, Dargvainiene J, et al
    In Vivo Measurement of Tau Depositions in Anti-IgLON5 Disease Using (18)F-PI-2620 PET.
    Neurology. 2023 Oct 25:10.1212/WNL.0000000000207870.
    PubMed     Abstract available
    
    
    
79. BEAUCHAMP LC, Dore V, Villemagne VL, Xu S, et al
    Utilizing (18)F-AV-133 VMAT2 PET Imaging to Monitor Progressive Nigrostriatal Degeneration in Parkinson Disease.
    Neurology. 2023 Oct 10:10.1212/WNL.0000000000207748.
    PubMed     Abstract available
    
    
    September 2023
80. COOMANS EM, de Koning LA, Rikken RM, Verfaillie SC, et al
    Performance of a [(18)F]Flortaucipir PET Visual Read Method Across the Alzheimer Disease Continuum and in Dementia With Lewy Bodies.
    Neurology. 2023 Sep 25:10.1212/WNL.0000000000207794.
    PubMed     Abstract available
    
    
    
81. CHEVAL M, Rodrigo S, Leroy C, Taussig D, et al
    [(18)F]DPA-714 PET Imaging in the Presurgical Evaluation of Patients With Drug-Resistant Focal Epilepsy.
    Neurology. 2023 Sep 25:10.1212/WNL.0000000000207811.
    PubMed     Abstract available
    
    
    
82. MALPETTI M, Rabinovici GD
    From Clinical Trials to Memory Clinics, tau-PET Visual Reads Can Help Diagnosis and Patient Stratification.
    Neurology. 2023 Sep 25:10.1212/WNL.0000000000207935.
    PubMed    
    
    
    July 2023
83. DURCAN R, Roberts G, Hamilton CA, Donaghy PC, et al
    Serial Nigrostriatal Dopaminergic Imaging in Mild Cognitive Impairment With Lewy Bodies, Alzheimer Disease, and Age-Matched Controls.
    Neurology. 2023 Jul 31:10.1212/WNL.0000000000207621.
    PubMed     Abstract available
    
    
    
84. PROKOPIOU PC, Engels-Dominguez N, Schultz AP, Sepulcre J, et al
    Association of Novelty-Related Locus Coeruleus Function With Entorhinal Tau Deposition and Memory Decline in Preclinical Alzheimer Disease.
    Neurology. 2023 Jul 25:10.1212/WNL.0000000000207646.
    PubMed     Abstract available
    
    
    October 2022
85. CHUNG SJ, Kim YJ, Kim YJ, Lee HS, et al
    Association Between White Matter Networks and the Pattern of Striatal Dopamine Depletion in Patients With Parkinson Disease.
    Neurology. 2022 Oct 4. pii: WNL.0000000000201269.
    PubMed     Abstract available
    
    
    September 2022
86. KAMAGATA K, Andica C, Takabayashi K, Saito Y, et al
    Association of MRI Indices of Glymphatic System With Amyloid Deposition and Cognition in Mild Cognitive Impairment and Alzheimer Disease.
    Neurology. 2022 Sep 19. pii: WNL.0000000000201300.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Nuclear Medicine is free of charge.